Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

4218 - RING observational trial to compare T790M mutation testing in blood by different methodologies

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Beatriz Garcia-Pelaez

Citation

Annals of Oncology (2018) 29 (suppl_8): viii649-viii669. 10.1093/annonc/mdy303

Authors

B. Garcia-Pelaez1, E. Jantus2, A. Romero3, M. Molina4, A. Blasco Cordellat5, C. Perez-Barrios3, R. Rosell6, C. Camps7, M. Provencio Pulla8

Author affiliations

  • 1 Laboratory Of Oncology/pangaea Oncology, QUIRON-DEXEUS UNIVERSITY HOSPITAL, 08028 - Barcelona/ES
  • 2 Molecular Oncology Department, Hospital General Universitario Valencia, 46018 - Valencia/ES
  • 3 Liquid Biopsy Laboratory, H. UNIV. PUERTA DE HIERRO-MAJADAHONDA, Majadahonda/ES
  • 4 Quirón Dexeus University Hospital, Pangaea Biotech S.L., Barcelona/ES
  • 5 Medical Oncology, Hospital General Universitario Valencia, 46018 - Valencia/ES
  • 6 Cancer biology & Precision Medicine Program, Germans Trias I Pujol Science Inst., Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
  • 7 Medical Oncology, Consorcio Hospital General Universitario de Valencia, 46014 - Valencia/ES
  • 8 Servicio De Oncología Médica, Hospital Universitario Puerta de Hierro - Majadahonda, 28222 - Majadahonda/ES
More

Resources

Abstract 4218

Background

EGFR- mut NSCLC patients benefit from EGFR-TKIs therapy. However, most patients relapse within 1 to 2 years. In 40-60% of the cases, the mechanism of resistance is the emergence of the EGFR p.T790M mutation, and third generation TKIs have shown efficacy in this setting. The availability of new biopsies at relapse to TKIs is limited and guidelines recommend testing for the p.T790M in blood at relapse to TKIs, and rebiopsy only in case of a negative result. Several blood based methodologies for EGFR-mut detection have been developed, including some NGS approaches, but comparison studies are limited. We aim to evaluate the agreement, specificity and sensitivity of methodologies available for T790M testing in liquid biopsies and to determine the best pre-analytical conditions for T790M mutation identification.

Trial design

The RING is a non-PAS, non-interventional, cross-sectional, diagnostic study that will enroll 75 patients from different Spanish institutions. Blood samples will be collected at the time of progression to first and second generation TKIs, and sent to the laboratories participating in the study. Three DNA extraction procedures will be tested; Maxwell® RSC cfDNA (Promega), the QIAamp® Circulating Nucleic Acid Kit (Qiagen) and automatic extraction using Qiasymphony® (Qiagen). The presence of the p.T790M in the purified DNA will be tested by 7 methodologies, namely cobas® EGFR Mutation Test v2 (Roche Diagnostics), Therascreen EGFR Plasma RGQ PCR Kit (Qiagen), QuantStudio® 3D Digital PCR System (Applied Biosystems), a 5′-nuclease real-time PCR (Taqman®) assay in presence of PNA, BEAMing digital PCR (Sysmex Inostics), NGS with the Oncomine® panel for Ion Torrent (Thermofisher) and NGS with the Lung Cancer Panel for GeneReader® (Qiagen). The kappa coefficient values and its corresponding 95% confidence intervals (95% CI) will be used to assess the agreement between methodologies and the Intraclass Correlation Coefficients (ICC) and Bland & Altman plots to evaluate the concordance between quantitative methodologies. Finally, we calculate that 40 patients will have a re-biopsy mutation T790M analysis, which will be considered the gold standard to estimate the sensitivity and specificity of each method.

Clinical trial identification

Legal entity responsible for the study

Spanish Lung Cancer Group / Grupo Español de Cancer de Pulmon (Slcg/Gecp).

Funding

AstraZeneca.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings